| 產(chǎn)品編號 | D51753 |
| 英文名稱 | Baricitinib |
| 中文名稱 | |
| 別 名 | JAK1/JAK2 抑制劑 |
| 性 狀 | Lyophilized |
| 保存條件 | Store in dry, dark place for one year. |
| 產(chǎn)品介紹 |
Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in the United States. CAS號：1187594-09-7 分子式：C16H17N7O2S 分子量：371.42 MDL：MFCD27920779 級別：AR 純度：98% 外觀/性狀：類白色或白色結(jié)晶性粉末，無臭無味。 溶解性：在水中略溶，在熱水中溶解，在乙醇或丙酮中不溶，在氫氧化鈉試液中易溶。 敏感性：吸濕性 作用靶點(diǎn)：JAK; 作用通路：Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt; 描述：巴瑞克替尼 (Baricitinib) 是選擇性，可口服的 JAK1 和 JAK2 |
